SCHEMBL21856932

SCHEMBL21856932

COC(=O)c1ccc(-c2cnn[nH]2)cc1C(=O)OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.40
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
PDK2 Q15119 1/20 0.38
PDK4 Q16654 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
MAPT P10636 6/20 0.38
RAB9A P51151 5/20 0.38
ALPL P05186 2/20 0.38
POLB P06746 2/20 0.38
KDM4E B2RXH2 4/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
NPC1 O15118 4/20 0.37
SMN1; SMN2 Q16637 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30268344 1.00 TSHR (0.40) TSHRCA12CA1CA2CA7
SCHEMBL21857459 0.78 KDM4E (0.38) ALPLPOLBKDM4ECYP2D6CYP2C9
SCHEMBL29733451 0.77 CA12 (0.53) TSHRCA12CA1CA2CA7
SCHEMBL6466451 0.77 CA12 (0.53) TSHRCA12CA1CA2CA7
SCHEMBL9813479 0.75 CA12 (0.52) TSHRCA12CA1CA2CA7
SCHEMBL6777545 0.74 HDAC1 (0.47) TSHRCA12CA1CA2CA7
SCHEMBL21857178 0.74 PTGER2 (0.36) RAB9ANPC1SMN1; SMN2CASP3SENP8
SCHEMBL4811891 0.73 MKNK1 (0.52)
SCHEMBL25039007 0.72 MAP3K5 (0.44) TSHRPOLBCYP1A2SMN1; SMN2ALDH1A1
SCHEMBL2185846 0.71 HSD17B1 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 US disclosed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 CN disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 WO disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 TSHR 4576/4885CA12 4254/4885CA1 3596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.